hotspot -WSS

hotspot

author：leisure time 2025-10-01 00:48:02 - browse：4896

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Washington mulls new rules to avert another Change Healthcare

WSS

Readout Newsletter: Merck, Vertex, and Viking updates

Abortion pill case raises question: who can sue the FDA?

Food as medicine: Medically tailored meals may get standardized

WuXi out of biotech trade group, U.S. and China relations to blame

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

EPA limits use of carcinogenic gas for sterilizing medical devices

hotspot

hotspot

Lobbying power of AI, software-enabled devices

focus

Virginia high school admissions case could be legal follow

HHS secretary Becerra pressed on Change HealthCare cyberattack

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ebola: Gilead Sciences antiviral shows promise as new treatment

Medical records are filled with copy

Pushing for an NIH office for post

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

John Green on his newest strategy for fighting tuberculosis

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Male and female sex labels in research insufficient, scientists say

hotspot

Patient advocates debate FDA's accelerated approval process

HHS secretary Becerra pressed on Change HealthCare cyberattack

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Oprah kicked off a national conversation on obesity. Let's have it

As AI in medicine takes off, can 'human in the loop' prevent harm?

Washington mulls new rules to avert another Change Healthcare

hotspot

hotspot

Wikipedia

explore